Refine
Year of publication
Document Type
- Doctoral Thesis (8848)
- Journal article (8246)
- Complete part of issue (703)
- Book article / Book chapter (479)
- Book (218)
- Conference Proceeding (202)
- Preprint (129)
- Review (115)
- Master Thesis (104)
- Working Paper (104)
Language
- English (10717)
- German (8555)
- French (58)
- Multiple languages (22)
- Spanish (22)
- Russian (6)
- Italian (2)
- Portuguese (2)
Keywords
- Würzburg (736)
- Universität (668)
- Wuerzburg (666)
- Wurzburg (659)
- University (608)
- Organische Chemie (135)
- Psychologie (127)
- Anorganische Chemie (124)
- Maus (124)
- Toxikologie (123)
Institute
- Theodor-Boveri-Institut für Biowissenschaften (2244)
- Graduate School of Life Sciences (999)
- Physikalisches Institut (787)
- Institut für Anorganische Chemie (674)
- Medizinische Klinik und Poliklinik I (635)
- Institut für Psychologie (585)
- Institut für Organische Chemie (545)
- Medizinische Klinik und Poliklinik II (545)
- Neurologische Klinik und Poliklinik (501)
- Klinik und Poliklinik für Allgemein-, Viszeral-, Gefäß- und Kinderchirurgie (Chirurgische Klinik I) (500)
Schriftenreihe
- Cultural Animal Studies, Band 3 (24)
- Spezielle Didaktik der Sportarten (2)
- Aesthetische Eigenzeiten, 17 (1)
- Akten des ... Symposiums des Mediävistenverbandes; 13,2 (1)
- Alter Orient und Altes Testament : Sonderreihe Veröffentlichungen zur Kultur und Geschichte des Alten Orients ; 3 (1)
- Aventiuren; 13 (1)
- Berichte aus der Informatik (1)
- Deuterocanonical and Cognate Literature Studies (1)
- Deuterocanonical and Cognate Literature Yearbook (1)
- Epistemata. Reihe Literaturwissenschaft ; 483 (1)
Sonstige beteiligte Institutionen
- VolkswagenStiftung (24)
- Johns Hopkins School of Medicine (18)
- Fraunhofer-Institut für Silicatforschung ISC (8)
- IZKF Nachwuchsgruppe Geweberegeneration für muskuloskelettale Erkrankungen (7)
- Akademie der Wissenschaften und der Literatur, Mainz (6)
- DFG Forschungsgruppe 2757 / Lokale Selbstregelungen im Kontext schwacher Staatlichkeit in Antike und Moderne (LoSAM) (6)
- Clinical Trial Center (CTC) / Zentrale für Klinische Studien Würzburg (ZKSW) (5)
- Helmholtz Institute for RNA-based Infection Research (HIRI) (5)
- Johns Hopkins University School of Medicine (5)
- Universität Leipzig (5)
ResearcherID
- B-1911-2015 (1)
- B-4606-2017 (1)
- C-2593-2016 (1)
- D-1221-2009 (1)
- D-1250-2010 (1)
- D-3057-2014 (1)
- I-5818-2014 (1)
- J-8841-2015 (1)
- M-1240-2017 (1)
- N-2030-2015 (1)
EU-Project number / Contract (GA) number
- 669054 (47)
- 701983 (39)
- 602805 (25)
- 646737 (23)
- 682586 (23)
- 728018 (15)
- 224631 (10)
- 288566 (10)
- 602133 (10)
- 787937 (9)
- 244090 (7)
- 259867 (6)
- 309962 (6)
- 614623 (6)
- 643051 (6)
- 677819 (6)
- 823881 (6)
- 101007642 (5)
- 241778 (5)
- 311781 (5)
- 223153 (4)
- 226852 (4)
- 250194 (4)
- 311932 (4)
- 336012 (4)
- 336305 (4)
- 607051 (4)
- 617989 (4)
- 654148 (4)
- 678119 (4)
- 766118 (4)
- 813871 (4)
- 825575 (4)
- 848261 (4)
- 01EW1902 (3)
- 223138 (3)
- 223175 (3)
- 247919 (3)
- 261357 (3)
- 287320 (3)
- 289706 (3)
- 339306 (3)
- 667302 (3)
- 686070 (3)
- 721016 (3)
- 733297 (3)
- 759139 (3)
- 824128 (3)
- 018741 (2)
- 201099 (2)
- 227632 (2)
- 245009 (2)
- 250320 (2)
- 262055 (2)
- 265432 (2)
- 268985 (2)
- 277775 (2)
- 281338 (2)
- 304617 (2)
- 305312 (2)
- 308377 (2)
- 312325 (2)
- 315877 (2)
- 316704 (2)
- 318798 (2)
- 320377 (2)
- 327199 (2)
- 335568 (2)
- 340983 (2)
- 503474 (2)
- 602300 (2)
- 618045 (2)
- 633983 (2)
- 636930 (2)
- 669830 (2)
- 680966 (2)
- 693023 (2)
- 721394 (2)
- 722046 (2)
- 754658 (2)
- 758985 (2)
- 761307 (2)
- 764860 (2)
- 765937 (2)
- 847507 (2)
- 897276 (2)
- 946184 (2)
- 953327 (2)
- 011937 (1)
- 018696 (1)
- 026155 (1)
- 031A408B (1)
- 031A409B (1)
- 037220 (1)
- 037602 (1)
- 0800978 (1)
- 101003595 (1)
- 10100764 (1)
- 101015930 (1)
- 101016923 (1)
- 101030656 (1)
- 101034412 (1)
- 101041177 (1)
- 101042738 (1)
- 101045956 (1)
- 101052587 (1)
- 101065772 (1)
- 101069547 (1)
- 101076402 (1)
- 101079460 (1)
- 115300 (1)
- 115525 (1)
- 18741 (1)
- 19-COP-0031 (1)
- 20-3044-2-11 (1)
- 20100317 (1)
- 20100407 (1)
- 201024 (1)
- 201052 (1)
- 2016 FGR 0053 (1)
- 201962 (1)
- 2020010013 (1)
- 202088 (1)
- 202213 (1)
- 203291 (1)
- 211078 (1)
- 212372 (1)
- 212525 (1)
- 214469 (1)
- 216027 (1)
- 216886 (1)
- 222719 (1)
- 222943 (1)
- 223044 (1)
- 224635 (1)
- 227159 (1)
- 229289 (1)
- 229294 (1)
- 229571 (1)
- 230331-PROPEREMO (1)
- 232944 (1)
- 241447 (1)
- 241592 (1)
- 241719 (1)
- 241909 (1)
- 242175 (1)
- 242175-VascuBone (1)
- 242175‐VascuBone (1)
- 242257 (1)
- 243964 (1)
- 247447 (1)
- 249177 (1)
- 249929 (1)
- 250194-Carnivorom (1)
- 253511 (1)
- 257531 (1)
- 259735 (1)
- 259753 (1)
- 260338 (1)
- 260464 (1)
- 260986 (1)
- 261474 (1)
- 261492 (1)
- 26230120009 (1)
- 262773 (1)
- 266777 (1)
- 267436 (1)
- 268962 (1)
- 270089 (1)
- 270212 (1)
- 274769 (1)
- 27731 (1)
- 278864 (1)
- 278864-2 (1)
- 279062 (1)
- 286213 (1)
- 289442 (1)
- 289600 (1)
- 290605 (1)
- 291377 (1)
- 291840 (1)
- 294683 (1)
- 294823 (1)
- 296679 (1)
- 297557 (1)
- 303674 (1)
- 304961 (1)
- 305653 (1)
- 306387 (1)
- 306447 (1)
- 307701 (1)
- 307955 (1)
- 311575 (1)
- 312147 (1)
- 314911 (1)
- 316633 (1)
- 316790 (1)
- 318987 (1)
- 320570 (1)
- 322865 (1)
- 324612 (1)
- 339728 (1)
- 340602 (1)
- 506675 (1)
- 517836 (1)
- 602102 (1)
- 602531 (1)
- 602812 (1)
- 604391 (1)
- 606950 (1)
- 609,020 (1)
- 610307 (1)
- 613931 (1)
- 615613 (1)
- 616346 (1)
- 617891 (1)
- 634361 (1)
- 638536 (1)
- 638988 (1)
- 639445 (1)
- 640012 (1)
- 641458 (1)
- 641833 (1)
- 643238 (1)
- 644076 (1)
- 645993 (1)
- 647281 (1)
- 647426 (1)
- 649124 (1)
- 654000 (1)
- 660375 (1)
- 667421 (1)
- 667787 (1)
- 668036 (1)
- 668353 (1)
- 668679 (1)
- 677302 (1)
- 679288 (1)
- 681103 (1)
- 686271 (1)
- 692185 (1)
- 695376 (1)
- 696802 (1)
- 703227 (1)
- 715923 (1)
- 716344 (1)
- 720270 (1)
- 722064 (1)
- 723770 (1)
- 725832 (1)
- 739593 (1)
- 741491 (1)
- 755523 (1)
- 759206 (1)
- 776019 (1)
- 810850 (1)
- 812968 (1)
- 818182 (1)
- 818846 (1)
- 819800 (1)
- 834709 (1)
- 835102) (1)
- 836421 (1)
- 840741 (1)
- 848002 (1)
- 853546 (1)
- 853988 (1)
- 862665 (1)
- 871158 (1)
- 874758 (1)
- 874827 (1)
- 955910 (1)
- 955974 (1)
- 956414 (1)
- 956548 (1)
- 965286 (1)
- BWF/H/52228/2012/13.10.10-1/3.4,6 (1)
- CP22/00082 (1)
- CoG 721016–HERPES (1)
- ERC-2013-StG-336305 (1)
- ERC-2016-CoG 721016-HERPES (1)
- ERC-2018-ADG/NCI-CAD (1)
- ERC335568 (1)
- ESF-ZDEX 4.0 (1)
- ESF_14-BM-A55-0005_16 (1)
- EU (FP7/ 2007-2013) (1)
- EU-1650-0006 (1)
- EU250194 (1)
- FKZ01EW1902 (1)
- FOOD‑CT‑2004‑506378 (1)
- FP7-ICT MINIMAL (1)
- FP7/2007-2013 (1)
- HEALTH-F2-2009-241778 (1)
- HEALTHF2- 2008-201099 (1)
- LIFE12 BIO/AT/000143 (1)
- LIFE20 NAT/AT/000049 (1)
- LaserLab Europe (LLC001917) (1)
- PI21/00314 (1)
- PIEF-GA-2013-623006 (1)
- PITN-GA-2012-316704 (1)
- PTQ2020-011372 (1)
- QLK1-2001-01614 (1)
- RTI2018-093747-B-10 (1)
- ZAM 5-85018031 (1)
Delayed and limited administration of the JAKinib tofacitinib mitigates chronic DSS-induced colitis
(2023)
In inflammatory bowel disease, dysregulated T cells express pro-inflammatory cytokines. Using a chronic azoxymethane (AOM)/dextran sulfate sodium (DSS)-induced colitis model resembling ulcerative colitis, we evaluated whether and when treatment with the Janus kinase (JAK) inhibitor tofacitinib could be curative. Comparing the treatment with two and three cycles of tofacitinib medication in drinking water – intermittently with DSS induction – revealed that two cycles were not only sufficient but also superior over the 3-x regimen. The two cycles of the 2-x protocol paralleled the second and third cycles of the longer protocol. T cells were less able to express interferon gamma (IFN-γ) and the serum levels of IFN-γ, interleukin (IL)-2, IL-6, IL-17, and tumor necrosis factor (TNF) were significantly reduced in sera, while those of IL-10 and IL-22 increased under the 2-x protocol. Likewise, the frequency and effector phenotype of regulatory T cells (Tregs) increased. This was accompanied by normal weight gain, controlled clinical scores, and restored stool consistency. The general and histologic appearance of the colons revealed healing and tissue intactness. Importantly, two phases of tofacitinib medication completely prevented AOM-incited pseudopolyps and the hyper-proliferation of epithelia, which was in contrast to the 3-x regimen. This implies that the initial IBD-induced cytokine expression is not necessarily harmful as long as inflammatory signaling can later be suppressed and that time-restricted treatment allows for anti-inflammatory and tissue-healing cytokine activities.
Introduction
Human cytomegalovirus (HCMV) causes significant morbidity and mortality in allogeneic stem cell transplant (alloSCT) recipients. Recently, antiviral letermovir prophylaxis during the first 100 days after alloSCT replaced PCR-guided preemptive therapy as the primary standard of care for HCMV reactivations. Here, we compared NK-cell and T-cell reconstitution in alloSCT recipients receiving preemptive therapy or letermovir prophylaxis in order to identify potential biomarkers predicting prolonged and symptomatic HCMV reactivation.
Methods
To that end, the NK-cell and T-cell repertoire of alloSCT recipients managed with preemptive therapy (n=32) or letermovir prophylaxis (n=24) was characterized by flow cytometry on days +30, +60, +90 and +120 after alloSCT. Additionally, background-corrected HCMV-specific T-helper (CD4+IFNγ+) and cytotoxic (CD8+IFNγ+CD107a+) T cells were quantified after pp65 stimulation.
Results
Compared to preemptive therapy, letermovir prophylaxis prevented HCMV reactivation and decreased HCMV peak viral loads until days +120 and +365. Letermovir prophylaxis resulted in decreased T-cell numbers but increased NK-cell numbers. Interestingly, despite the inhibition of HCMV, we found high numbers of “memory-like” (CD56dimFcεRIγ- and/or CD159c+) NK cells and an expansion of HCMV-specific CD4+ and CD8+ T cells in letermovir recipients. We further compared immunological readouts in patients on letermovir prophylaxis with non/short-term HCMV reactivation (NSTR) and prolonged/symptomatic HCMV reactivation (long-term HCMV reactivation, LTR). Median HCMV-specific CD4+ T-cell frequencies were significantly higher in NSTR patients (day +60, 0.35 % vs. 0.00 % CD4+IFNγ+/CD4+ cells, p=0.018) than in patients with LTR, whereas patients with LTR had significantly higher median regulatory T-cell (Treg) frequencies (day +90, 2.2 % vs. 6.2 % CD4+CD25+CD127dim/CD4+ cells, p=0.019). ROC analysis confirmed low HCMV specific CD4+ (AUC on day +60: 0.813, p=0.019) and high Treg frequencies (AUC on day +90: 0.847, p=0.021) as significant predictors of prolonged and symptomatic HCMV reactivation.
Discussion
Taken together, letermovir prophylaxis delays HCMV reactivation and alters NK- and T-cell reconstitution. High numbers of HCMV-specific CD4+ T cells and low numbers of Tregs seem to be pivotal to suppress post-alloSCT HCMV reactivation during letermovir prophylaxis. Administration of more advanced immunoassays that include Treg signature cytokines might contribute to the identification of patients at high-risk for long-term and symptomatic HCMV reactivation who might benefit from prolonged administration of letermovir.
Myeloid-derived suppressor cells (MDSC) represent major regulators of immune responses, which can control T cells via their inducible nitric oxide synthase (iNOS)- and arginase 1 (Arg1)-mediated effector functions. While GM-CSF is well documented to promote MDSC development, little is known about this potential of IL-3, an established growth factor for mast cells. Here, we show that IL-3, similar to GM-CSF, generates monocytic MDSC (M-MDSC) from murine bone marrow (BM) cells after 3 days of in vitro culture. At this time point, predominantly CD11b+ CD49a+ monocytic and CD11b+ CD49a- FcεR I- neutrophilic cells were detectable, while CD11blow/neg FcεR I+ mast cells accumulated only after extended culture periods. Both growth factors were equivalent in generating M-MDSC with respect to phenotype, cell yield and typical surface markers. However, IL-3 generated M-MDSC produced less TNF, IL-1β and IL-10 after activation with LPS + IFN-γ but showed higher Arg1 expression compared to GM-CSF generated M-MDSC. Arg1 was further induced together with iNOS after MDSC activation. Accordingly, an increased Arg1-dependent suppressor activity by the IL-3 generated M-MDSC was observed using respective iNOS and Arg1 inhibitors. Together, these data indicate that M-MDSC can be generated in vitro by IL-3, similar to GM-CSF, but with increased Arg1 expression and Arg1-mediated suppression capacity. This protocol now allows further in vitro studies on the role of IL-3 for MDSC biology.
Next-generation humanized NSG-SGM3 mice are highly susceptible to Staphylococcus aureus infection
(2023)
Humanized hemato-lymphoid system mice, or humanized mice, emerged in recent years as a promising model to study the course of infection of human-adapted or human-specific pathogens. Though Staphylococcus aureus infects and colonizes a variety of species, it has nonetheless become one of the most successful human pathogens of our time with a wide armory of human-adapted virulence factors. Humanized mice showed increased vulnerability to S. aureus compared to wild type mice in a variety of clinically relevant disease models. Most of these studies employed humanized NSG (NOD-scid IL2Rgnull) mice which are widely used in the scientific community, but show poor human myeloid cell reconstitution. Since this immune cell compartment plays a decisive role in the defense of the human immune system against S. aureus, we asked whether next-generation humanized mice, like NSG-SGM3 (NOD-scid IL2Rgnull-3/GM/SF) with improved myeloid reconstitution, would prove to be more resistant to infection. To our surprise, we found the contrary when we infected humanized NSG-SGM3 (huSGM3) mice with S. aureus: although they had stronger human immune cell engraftment than humanized NSG mice, particularly in the myeloid compartment, they displayed even more pronounced vulnerability to S. aureus infection. HuSGM3 mice had overall higher numbers of human T cells, B cells, neutrophils and monocytes in the blood and the spleen. This was accompanied by elevated levels of pro-inflammatory human cytokines in the blood of huSGM3 mice. We further identified that the impaired survival of huSGM3 mice was not linked to higher bacterial burden nor to differences in the murine immune cell repertoire. Conversely, we could demonstrate a correlation of the rate of humanization and the severity of infection. Collectively, this study suggests a detrimental effect of the human immune system in humanized mice upon encounter with S. aureus which might help to guide future therapy approaches and analysis of virulence mechanisms.
Many new immunotherapeutic approaches aim on the stimulatory targeting of receptors of the tumor necrosis factor (TNF) receptor superfamily (TNFRSF) using antibodies with intrinsic or conditional agonism. There is an initial need to characterize corresponding TNFRSF receptor (TNFR)-targeting antibodies with respect to affinity, ligand binding, receptor activation and the epitope recognized. Here, we report a collection of simple and matched protocols enabling the detailed investigation of these aspects by help of Gaussia princeps luciferase (GpL) fusion proteins and analysis of interleukin-8 (IL8) production as an easily measurable readout of TNFR activation. In a first step, the antibodies and antibody variants of interest are transiently expressed in human embryonal kidney 293 cells, either in non-modified form or as fusion proteins with GpL as a reporter domain. The supernatants containing the antibody-GpL fusion proteins can then be used without further purification in cell-free and/or cellular binding studies to determine affinity. Similarly, binding studies with mutated TNFR variants enable the characterization of the antibody binding site within the TNFR ectodomain. Furthermore, in cellular binding studies with GpL fusion proteins of soluble TNFL molecules, the ability of the non-modified antibody variants to interfere with TNFL-TNFR interaction can be analyzed. Last but not least, we describe a protocol to determine the intrinsic and the Fc gamma receptor (FcγR)-dependent agonism of anti-TNFR antibodies which exploits i) the capability of TNFRs to trigger IL8 production in tumor cell lines lacking expression of FcγRs and ii) vector- and FcγR-transfected cells, which produce no or only very low amounts of human IL8. The presented protocols only require standard molecular biological equipment, eukaryotic cell culture and plate readers for the quantification of luminescent and colorimetric signals.
B cell maturation and immunoglobulin (Ig) repertoire selection are governed by expression of a functional B cell receptor (BCR). Naïve B cells co-express their BCR as IgM and IgD isotype. However, the role of the additionally expressed IgD on naïve B cells is not known. Here we assessed the impact of IgD on naïve B cell maturation and Ig repertoire selection in 8 individuals from 3 different families with heterozygous loss-of-function or loss-of expression mutations in IGHD. Although naïve B cells from these individuals expressed IgM on their surface, the IGHD variant in heterozygous state entailed a chimeric situation by allelic exclusion with almost half of the naïve B cell population lacking surface IgD expression. Flow cytometric analyses revealed a distinct phenotype of IgD-negative naïve B cells with decreased expression of CD19, CD20 and CD21 as well as lower BAFF-R and integrin-β7 expression. IgD-negative B cells were less responsive in vitro after engaging the IgM-BCR, TLR7/9 or CD40 pathway. Additionally, a selective disadvantage of IgD-negative B cells within the T2 transitional and mature naïve B cell compartment as well as reduced frequencies of IgMlo/- B cells within the mature naïve B cell compartment lacking IgD were evident. RNA-Ig-seq of bulk sorted B cell populations showed an altered selection of distinct VH segments in the IgD-negative mature naïve B cell population. We conclude that IgD expression on human naïve B cells is redundant for generation of naïve B cells in general, but further shapes the naive B cell compartment starting from T2 transitional B cells. Our observations suggest an unexpected role of IgD expression to be critical for selection of distinct Ig VH segments into the pre-immune Ig repertoire and for the survival of IgMlo/- naïve B cells known to be enriched in poly-/autoreactive B cell clones.
Infections with influenza A viruses (IAV) cause seasonal epidemics and global pandemics. The majority of these infections remain asymptomatic, especially among children below five years of age. Importantly, this is a time, when immunological imprinting takes place. Whether early-life infections with IAV affect the development of antimicrobial immunity is unknown. Using a preclinical mouse model, we demonstrate here that silent neonatal influenza infections have a remote beneficial impact on the later control of systemic juvenile-onset and adult-onset infections with an unrelated pathogen, Staphylococcus aureus, due to improved pathogen clearance and clinical resolution. Strategic vaccination with a live attenuated IAV vaccine elicited a similar protection phenotype. Mechanistically, the IAV priming effect primarily targets antimicrobial functions of the developing innate immune system including increased antimicrobial plasma activity and enhanced phagocyte functions and antigen-presenting properties at mucosal sites. Our results suggest a long-term benefit from an exposure to IAV during the neonatal phase, which might be exploited by strategic vaccination against influenza early in life to enforce the host’s resistance to later bacterial infections.
Introduction
In patients with peripheral neuropathies (PNP), neuropathic pain is present in 50% of the cases, independent of the etiology. The pathophysiology of pain is poorly understood, and inflammatory processes have been found to be involved in neuro-degeneration, -regeneration and pain. While previous studies have found a local upregulation of inflammatory mediators in patients with PNP, there is a high variability described in the cytokines present systemically in sera and cerebrospinal fluid (CSF). We hypothesized that the development of PNP and neuropathic pain is associated with enhanced systemic inflammation.
Methods
To test our hypothesis, we performed a comprehensive analysis of the protein, lipid and gene expression of different pro- and anti-inflammatory markers in blood and CSF from patients with PNP and controls.
Results
While we found differences between PNP and controls in specific cytokines or lipids, such as CCL2 or oleoylcarnitine, PNP patients and controls did not present major differences in systemic inflammatory markers in general. IL-10 and CCL2 levels were related to measures of axonal damage and neuropathic pain. Lastly, we describe a strong interaction between inflammation and neurodegeneration at the nerve roots in a specific subgroup of PNP patients with blood-CSF barrier dysfunction.
Conclusion
In patients with PNP systemic inflammatory, markers in blood or CSF do not differ from controls in general, but specific cytokines or lipids do. Our findings further highlight the importance of CSF analysis in patients with peripheral neuropathies.
The Carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1), also known as CD66a, is a member of the immunoglobulin superfamily. CEACAM1 was shown to be a prognostic marker in patients suffering from cancer. In this review, we summarize pre-clinical and clinical evidence linking CEACAM1 to tumorigenicity and cancer progression. Furthermore, we discuss potential CEACAM1-based mechanisms that may affect cancer biology.
The opportunities genetic engineering has created in the field of adoptive cellular therapy for cancer are accelerating the development of novel treatment strategies using chimeric antigen receptor (CAR) and T cell receptor (TCR) T cells. The great success in the context of hematologic malignancies has made especially CAR T cell therapy a promising approach capable of achieving long-lasting remission. However, the causalities involved in mediating resistance to treatment or relapse are still barely investigated. Research on T cell exhaustion and dysfunction has drawn attention to host-derived factors that define both the immune and tumor microenvironment (TME) crucially influencing efficacy and toxicity of cellular immunotherapy. The microbiome, as one of the most complex host factors, has become a central topic of investigations due to its ability to impact on health and disease. Recent findings support the hypothesis that commensal bacteria and particularly microbiota-derived metabolites educate and modulate host immunity and TME, thereby contributing to the response to cancer immunotherapy. Hence, the composition of microbial strains as well as their soluble messengers are considered to have predictive value regarding CAR T cell efficacy and toxicity. The diversity of mechanisms underlying both beneficial and detrimental effects of microbiota comprise various epigenetic, metabolic and signaling-related pathways that have the potential to be exploited for the improvement of CAR T cell function. In this review, we will discuss the recent findings in the field of microbiome-cancer interaction, especially with respect to new trajectories that commensal factors can offer to advance cellular immunotherapy.